Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Felix-Hausdorff-Straße 3, 17489, Greifswald, Germany.
Research, Development & Innovation, Evonik Operations GmbH, Kirschenallee, 64293, Darmstadt, Germany.
AAPS PharmSciTech. 2021 Dec 27;23(1):39. doi: 10.1208/s12249-021-02176-7.
The present study focused on establishing a novel, (pre-)screening approach that enables the development of promising performing self-nanoemulsifying drug delivery systems (SNEDDSs) with a limited number of experiments. The strategic approach was based on first identifying appropriate excipients (oils/lipids, surfactants, and co-solvents) providing a high saturation solubility for lipophilic model compounds with poor aqueous solubility. Excipients meeting these requirements were selected for SNEDDS development, and a special triangular mixture design was applied for determining excipient ratios for the SNEDDS formulations. Celecoxib and fenofibrate were used as model drugs. Formulations were studied applying a specific combination of in vitro characterization methods. Specifications for a promising SNEDDS formulation were self-imposed: a very small droplet size (< 50 nm), a narrow size distribution of these droplets (PDI < 0.15) and a high transmittance following SNEDDS dispersion in water (> 99% in comparison with purified water). Excipients that provided a nanoemulsion after dispersion were combined, and ratios were optimized using a customized mapping method in a triangular mixture design. The best performing formulations were finally studied for their in vitro release performance. Results of the study demonstrate the efficiency of the customized screening tool approach. Since it enables successful SNEDDS development in a short time with manageable resources, this novel screening tool approach could play an important role in future SNEDDS development. Graphical abstract.
本研究旨在建立一种新颖的(预)筛选方法,该方法可以通过有限数量的实验来开发有前途的自微乳给药系统(SNEDDS)。该策略方法基于首先确定合适的辅料(油/脂、表面活性剂和共溶剂),以提供具有较差水溶解度的亲脂性模型化合物的高饱和溶解度。选择符合这些要求的辅料用于 SNEDDS 开发,并应用特殊的三角混合物设计来确定 SNEDDS 配方的辅料比例。塞来昔布和非诺贝特被用作模型药物。通过应用特定的体外特性组合方法来研究制剂。对有前途的 SNEDDS 制剂的规格进行了自我限制:非常小的液滴尺寸(<50nm),这些液滴的窄粒径分布(PDI<0.15)以及在水(与纯化水相比>99%)中分散后的高透光率。在分散后提供纳米乳液的辅料被组合在一起,并使用定制的映射方法在三角混合物设计中优化比例。最后,对最佳性能的制剂进行体外释放性能研究。研究结果表明,定制筛选工具方法的效率很高。由于它可以在短时间内使用可管理的资源成功开发 SNEDDS,因此这种新型筛选工具方法在未来的 SNEDDS 开发中可能发挥重要作用。图形摘要。